Carollina Mariga

Mrs. Carollina Mariga

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Acta Scientiae Veterinariae
Verified
Journal Article
Open access
CMCarollina Mariga
Carollina Mariga
OSOtávio Henrique de Melo Schiefler
Otávio Henrique de Melo Schiefler
JNJelson Norberto Nauderer
Jelson Norberto Nauderer
ASAna Paula Da Silva
Ana Paula Da Silva
NBNathieli Bianchin Bottari
Nathieli Bianchin Bottari
SFSaulo Tadeu Lemos Pinto Filho
Saulo Tadeu Lemos Pinto Filho
Background: O sistema endocanabinoidoma (eCBoma) é um complexo de interações entre substâncias endocanabinoides, enzimas e diversos receptores presentes em todo o organismo. Dessa forma, a terapia canábica, com seus fitocanabinoides, entra como um potencial terapêutico muito pesquisado em outras áreas, mas ainda escasso na veterinária. Destaca-se a potencial utilização dessa terapia em cães com dermatite atópica, a segunda dermatopatia alérgica mais presente na rotina clínica e que representa um desafio terapêutico quando se trata de controle dos sinais clínicos. O objetivo deste trabalho é relatar um caso de associação do óleo de cannabis com a ciclosporina em um cão. Case: Foi atendido no Hospital Veterinário Universitário de uma Instituição de Ensino Superior, um canino, fêmea, castrada, oito anos de idade, sem raça definida com diagnóstico anterior de dermatite atópica e histórico de terapias com resultados ineficientes. No atendimento foram solicitados para avaliação o perfil de estresse oxidativo e histopatologia de pele, com contagem de mastócitos, para avaliação da eficácia da associação, além de mensuração de glicemia, aferição de pressão arterial sistólica e coleta de sangue para hemograma e perfil bioquímico para avaliar a eficácia do tratamento utilizado. Outra forma de avaliação utilizada foi a percepção do tutor frente à adaptação ao novo tratamento com relação ao prurido, lesões de pele e efeitos adversos, por meio de um questionário. Como tratamento foi instituído a utilização da ciclosporina (Cyclavance®), na dose de 1,25mg/kg, SID em associação com oléo cannabis full spectrum high canabidiol (CBD) 4%, sendo este utilizado 8 gotas uma vez ao dia durante 60 dias. Os banhos com shampoo cloresten® foram mantidos. Segundo a percepção do tutor o animal apresentou uma boa aceitação ao tratamento, relatando como efeitos adversos sonolência, hiperexia, ganho de peso e comportamento mais calmo, os quais não foram prejudiciais ao animal, não necessitando interromper o tratamento. Foram verificados diminuição dos níveis de glicemia, aumento de substâncias antioxidantes e diminuição do prurido. Discussion: A dermatite atópica canina é caracterizada como uma doença cutânea alérgica mais frequentemente diagnosticada em cães, com uma patogenia multifatorial e de controle desafiador, necessitando do uso de tratamento contínuo ao logo da vida do paciente. A opção mais utilizada comercialmente é a ciclosporina. A ciclosporina é uma medicação inibidora de cálcio que se liga ao citoplasma de linfócitos e inibe a translocação do fator nuclear de células T ativadas para o núcleo, regulando negativamente a síntese de diversas citocinas como IL-2 e IFNγ. O sistema endocanabinóide tem seus receptores CB1 e CB2 localizados em diversas partes do organismo, inclusive na pele, com funções de manutenção da barreira cutânea, de crescimento e diferenciação celular, processos imunológicos e inflamatórios. A particularidade do eCBoma na pele é um alvo terapêutico em ascensão. Pelos seus receptores, presentes em células específicas da pele, tornam-se alvos de diferentes terapias em diversas doenças que acomete o maior órgão do corpo, principalmente devido às propriedade anti-inflamatórias, antioxidantes e analgésicas. Não apenas presente na pele, esse sistema possui influência entre diferentes mecanismos como a regulação da glicemia, pressão sistêmica e aumento de substâncias antioxidantes no organismo. Sabe-se da importância dos efeitos do excesso de radicais livres na homeostase do organismo e sua relação direta com o aparecimento de doenças, sendo desta forma não importante o conhecimento a cerca do estudo de moléculas antioxidades como o CBD, promovendo um aumento desses antioxidantes no organismo, mantendo o equilíbrio do sistema endocanabinóide. Conclui-se que o óleo de Cannabis é promissor quando em associação com ciclosporina a fim de controle dos sinais clínicos da dermatite atópica canina, melhorando desta forma a qualidade de vida do paciente.

6 April 2023 in Journal Archives of Health
Verified
Journal Article
Open access
PDF file
CMCarollina Mariga
Carollina Mariga
EVEduarda Laís Villa
Eduarda Laís Villa
ADAngela Isabel dos Santos Dullus Dullius
Angela Isabel dos Santos Dullus Dullius
AKAlexandre Krause
Alexandre Krause
SFSaulo Tadeu Lemos Pinto Filho
Saulo Tadeu Lemos Pinto Filho
Por meio de estudo retrospectivo, do período de janeiro de 2017 a maio de 2019, 289 animais foram testados para FIV e FeLV e os resultados foram destinados a análises de alterações hematológicas apresentadas. O teste estatístico utilizado para a associação foi o teste do qui-quadrado ao nível de 5% de significância. Desta amostra total, 208 (71,97%) animais foram negativos ao teste imunocromatográfico, enquanto 81 (28,03%) foram positivos. Destes positivos 14 (17,28%) eram apenas FIV positivos, 51 (62,96%) eram apenas FeLV e 16 (19,75%) eram FIV e FeLV positivos. Os resultados estatísticos revelaram que o perfil de risco na FeLV está relacionado à idade, principalmente animais de 0 a 3 anos de idade, enquanto que no perfil de risco do FIV prevaleceram machos não castrados. Nos achados hematológicos, estatisticamente houve relação entre FeLV e baixa contagem de hemácias e concentração de hemoglobina, enquanto infecções concomitantes de FIV e FeLV apresentaram relação com baixa contagem de hemácias. Valores dentro dos limites de referência, mas com diferença estatística, foram observados para leucócitos totais em animais FeLV positivos. Conclui-se que gatos acometidos por FIV são principalmente machos inteiros, enquanto pelo FeLV são animais jovens, de até 3 anos de idade, que se apresentam anêmicos e níveis normais de leucócitos, enquanto nos coinfectados a anemia é a principal alteração.

1 March 2023 in Archives of Veterinary Science
Verified
Journal Article
Open access
LMLetícia Reginato Martins
Letícia Reginato Martins
NFNadine Trinks Fischborn
Nadine Trinks Fischborn
CMCarollina Mariga
Carollina Mariga
JGJúlia Mariani Griesang
Júlia Mariani Griesang
JAJúlia Carneiro Rodrigues Andrade
Júlia Carneiro Rodrigues Andrade
MBMaurício Veloso Brun
Maurício Veloso Brun
This study aimed to determine whether hyperbaric oxygen therapy (HBOT) alters oxidative biomarkers after elective ovariohysterectomy (OHE). For this purpose, 45 healthy female cats were randomized into three groups: the hyperbaric group (HG): 15 animals pretreated with HBOT and submitted to OHE; the hyperbaric control group (HCG): 15 animals pretreated with HBOT without surgery; and the sham group (SHAM): 15 female cats submitted to OHE without pretreatment. The following biomarkers were evaluated: superoxide dismutase (SOD) and catalase (CAT), reactive oxygen species (ROS), thiobarbituric acid reactive substances (TBARS), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE). The collection times were: T1 = before the surgery for the operated groups and after sedation in the HCG; T2 = 30 min after reversal of sedation (HCG) or at the time of extubation in the other groups; T3 = 24 hr after T2. There was no difference regarding serum dosage of ROS, AChE, or BChE. There was an increase in TBARS in the T3 SHAM compared to the T3 HG (p=0.043). Moreover, CAT activity decreased in T2 SHAM and T3 SHAM compared to T1 SHAM (p=0.012 and p<0.001mauric); T2 SHAM had lower CAT activity than T2 HCG (p=0.05). Additionally, the T3 SHAM was lower than the T3 HG (p=0.030) and T3 HCG (p=0.050). There was reduced SOD in the T2 SHAM compared to the T2 HG (p=0.033) and T2 HCG (p=0.027). Similarly, the T3 SHAM decreased compared to the T3 HG (p=0.039) and T3 HCG (p=0.019).

13 March 2024 in Acta Scientiae Veterinariae
Verified
Journal Article
Open access
PDF file
CMCarollina Mariga
Carollina Mariga
EVEduarda Laís Villa
Eduarda Laís Villa
AJArthur Viana Joner
Arthur Viana Joner
BFBruna Pacheco de Freitas
Bruna Pacheco de Freitas
PCPaloma Félix Coelho
Paloma Félix Coelho
SFSaulo Tadeu Lemos Pinto Filho
Saulo Tadeu Lemos Pinto Filho
Background: The therapy for controlling Canine Atopic Dermatitis (CAD) involves a multidrug approach, which can often lead to frustration for both the responsible veterinarian and the owner When a satisfactory clinical response is not achieved. There is an increasing need to offer new options, especially in cases that are recurrent and challenging to control. Cannabis is becoming increasingly relevant for various therapies, and the unique presence of the endocannabinoid system (ECS) in specific skin cells makes it a candidate with high potential for treating this syndrome. Due to this Strong connection between cannabis and therapeutic potential in the skin, combined with the difficulty of control, this work aimed to evaluate the safety of cannabinoid therapy considering it as a possible future treatment option for canine atopic dermatitis. Material, Methods and Results: For this, fourteen canines with atopic dermatitis were divided into two groups: the treated group [using full-spectrum cannabis oil with a higher prevalence of cannabidiol (CBD)1] and the control group (treated with olive oil). The evaluation methods for the safety of the therapy were based on the evaluation of behavior, measurement of temperature and systolic blood pressure2, blood glucose3, and blood tests. The measurements were compared at the pre-treatment stage and at 60 days into the treatment with a protocol involving two administrations per day at a dosage of 2.5 mg/kg. Despite some significances, this work did not obtain statistically achieved results between the compared treatments. Discussion: The World Health Organization (WHO) acknowledges the safety of treatment with canabidiol (CBD), but there is still limited research on its clinical applicability in veterinary medicine. Although not completely elucidated, the ECS plays a role in regulating anxiety and stress responses, with its effects dependent on oil profile, dosage, route of administration, as well as individual patient characteristics, which may explain the absence of significant findings. The ECS also effects cardiovascular function by controlling vascular tone, cardiac contractility, blood pressure, and vascular inflammation, which can result in hypo- or hypertension, as well as bradycardia or tachycardia. Despite the involvement of various receptors, there is currently no literature evaluating blood pressure similar to this study. Cannabinoids are also capable of dose-dependent alteration in body temperature, causing hypothermia at high doses and hyperthermia at low doses, through neurochemical mediators both pre- and postsynaptically or by directly acting on the hypothalamus. Temperature measurements remained within normal ranges, highlighting their safety in terms of thermoregulation. The ECA regulates blood glucose levels by modulating glycogenesis, glycogenolysis, and insulin activity in tissues; therefore, even with its direct and indirect action on pancreatic cells, it did not significantly alter glucose levels in animals within physiological ranges. In contrast, the blood test values, with alterations primarily related to red blood cell count and eosinophils, do not have current literature linking them to cannabis. On a biochemical level, while some studies report dose- and time-dependent increases in alkaline phosphatase (ALP), it is important to emphasize the safety of the present protocol. Like the literature, this study also presents occasional, mild, and self-limiting adverse effects. It is concluded that full-spectrum cannabis oil high CBD has good safety and high tolerability for future adjunctive treatment to multimodal therapy of canine atopic dermatitis.

1 November 2022 in Revista Agraria Academica
Verified
Journal Article
Closed access
UMUniversidade Federal de Santa Maria
Universidade Federal de Santa Maria
LMLetícia Reginato Martins
Letícia Reginato Martins
LTLuciana Gonçalves Teixeira
Luciana Gonçalves Teixeira
MLMarcella Teixeira Linhares
Marcella Teixeira Linhares
JFJoão Pedro Scussel Ferranti
João Pedro Scussel Ferranti
ASAndré Vasconcelos Soares
André Vasconcelos Soares
This randomized blinded study objected to investigate a local anesthesia (0,5% bupivacaine) in the surgical incision site in dogs underwent to ovariohysterectomy by celiotomy or video-assisted by two-portal. Twenty-eight healthy adults were selected. Dogs were divided into celiotomy control group, celiotomy blocking group (BC), video-assisted control group and blocking video-assisted group (BV). In the BC and BV, bupivacaine was administered SC in the incision line or port sites. Control groups received NaCl 0,9% at the same sites. Three evaluators blinded evaluated postoperative pain, using Melbourne Pain Scale and visual analog scale. The anesthetic infiltrative blockade used was efficient in promoting postoperative comfort in both celiotomy and video assisted OVH.

14 October 2026 in Frontiers in Allergy
Verified
Journal Article
Open access
PDF file
CMCarollina Mariga
Carollina Mariga
FSFilipe Costa da Silva
Filipe Costa da Silva
OSOtávio Henrique de Melo Schiefler
Otávio Henrique de Melo Schiefler
EAErik Amazonas
Erik Amazonas
AMAna Lucia Souza Silva Mateus
Ana Lucia Souza Silva Mateus
SFSaulo Tadeu Lemos Pinto Filho
Saulo Tadeu Lemos Pinto Filho
Canine atopic dermatitis is a multifactorial chronic skin disease that is difficult to control and requires lifelong and multimodal therapy. Cannabis has regained medical relevance in several fields, particularly in dermatology, as the endocannabinoid system is uniquely expressed in skin tissues and cells. Modulation through cannabinoids aims to restore skin homeostasis by reducing oxidative stress, inflammation, and consequently the clinical signs exhibited by animals with dermatopathies. This study aimed to evaluate Cannabis oil as a therapeutic option for dogs with atopic dermatitis, for both managing recurrent clinical signs and for enabling oclacitinib dose reduction. Sixteen dogs with atopic dermatitis previously treated with oclacitinib without satisfactory improvement were selected. All dogs underwent a fixed-sequence repeated-measures protocol consisting of four standardized evaluation stages: T0 (oclacitinib alone), T30 (placebo + oclacitinib), T60 (Cannabis oil + oclacitinib), and T90 (Cannabis oil + oclacitinib at 50% reduced dose). Dermatological assessments were performed at each stage to monitor clinical progression and response, including CADESI-4, performed by a veterinary dermatologist, and pruritus scoring, reported by the owners; both were blinded to whether the animal was receiving placebo (mineral oil) or Cannabis oil. Of the 16 enrolled dogs, fourteen completed all study stages through T90. No statistically significant difference was observed for CADESI-4. Likewise, no significant difference in pruritus was observed between T30 (placebo) and T60 (Cannabis oil); however, a significant reduction in pruritus was found between T0 x T60 ( p = 0.0010), and T0 x T90 ( p = 0.0025). Mild, transient, and self-limiting adverse events, as reported by the owners, were observed during both the placebo and Cannabis oil treatment periods. It is concluded that adjunctive Cannabis oil contributed to improved pruritus control in dogs with atopic dermatitis. In addition, maintenance of pruritus scores was observed following a predefined 50% reduction in oclacitinib dosage, supporting further investigation of Cannabis oil as part of a multimodal therapeutic strategy for canine atopic dermatitis.